Remedy & Company Corporation joins to GHIT Fund, a Public Interest Incorporated Association, as an Associate Partner.

We are pleased to announce that Remedy & Company Corporation (Chiyoda-ku, Tokyo, Founder and CEO Masakuni Ukita and hereinafter “Remedy & Company”) has decided to join and contribute as an Associate Partner to the Global Health Innovative Technology (GHIT) Fund, a Public Interest Incorporated Association, in alignment with its mission.

GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). It is dedicated to advancing the development of treatments, vaccines, and diagnostics for infectious diseases that threaten the health of the world's underserved populations.

Remedy & Company is committed to GHIT Fund's mission of fighting infectious diseases through the utilization of innovative drug discovery technologies and solutions originating in Japan. We aim to contribute to the development of new drugs, improvement of medical access, and global infectious disease prevention efforts while preparing for the occurrence of the next pandemic. As such, we are proud to become an Associate Partner of GHIT Fund.

CEO of the GHIT Fund, Mr. Osamu Kunii:
“We are delighted to be working with Remedy & Company, a company that empathizes with the GHIT Fund's vision and mission and is committed to the use of technology to solve global health challenges. We anticipate that Remedy& Company will leverages their experience and expertise in clinical trials around the world, particularly in developing countries, to help accelerate GHIT’s products development.”

Founder and CEO of Remedy & Company Corporation, Mr. Masakuni Ukita:
As a Japanese multinational corporation, we have developed expertise in global clinical development. By combining this with our healthcare DX solutions, we believe we can contribute to GHIT Fund's vision for global health.
Therefore, we have decided to participate as a funding partner. We hold great passion and expectations for GHIT Fund's leadership and, in the spirit of “All Japan,” we will stand together with GHIT Fund to combat infectious diseases worldwide.

In the recent pandemic of coronavirus (COVID-19) the world has severely changed from 2019, research and development of diagnostic tests, vaccines, and treatments were rapidly conducted in countries worldwide, in collaboration between government and private sectors. Remarkably, new drugs were successfully developed in less than a year from the onset of the pandemic. However, given the unpredictable nature of when the next pandemic might occur, there is a global demand for strategies that can achieve the development and practical application of treatments and vaccines within a shorter timeframe. Moreover, efforts are needed to ensure equitable distribution of these medical solutions to countries worldwide. In this context, the “100 Days Mission” was proposed during the G7 Summit held in the United Kingdom in June 2021.

We are proud to announce our partnership with the GHIT Fund as an Associate Partner. Through this collaboration, we aim to contribute to the research and development of vaccines and treatments for existing infectious diseases in various regions, as well as preparedness for future pandemics. Our goal is to support the advancement of the “100 Days Mission” and work towards resolving global health challenges from Japan to the world.

About “100 Days Mission”
The “100 Days Mission” is an international goal that aims to achieve the practical application of “Medical Countermeasures (MCM)” within 100 days from the declaration of a “Public Health Emergency of International Concern (PHEIC)” by the World Health Organization (WHO) for a new infectious disease. This goal was proposed during the G7 Summit held in the United Kingdom in June 2021, in response to the challenges highlighted by the global spread of the novel coronavirus (COVID-19). MCM includes the approval of rapid diagnostic tests, safe and effective vaccines, and the establishment of treatments, among other measures.

About GHIT Fund:
The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org

About Remedy & Company:
Remedy & Company Corporation (formerly known as intellim Holdings Corporation) was established in 2018. Its predecessor, intellim Corporation, which was founded in 2005 with main aim of developing CRO business. Subsequently, intellim Holdings Corporation (now known as Remedy & Company Corporation) was established in 2018 as the core driving intellim Corporation and other group companies in Japan and abroad to create innovative solutions in drug development within Japan and abroad. In April 2022, the company changed its name to Remedy & Company Corporation and made a new start with the goal of becoming a global health tech platform that transcends the boundaries of a CRO. Remedy & Company Corporation oversees group companies including intellim Corporation, iRIS Corporation, Quantum Healthcare Corporation and Remedy XR Corporation, and its business objective is to achieve further growth for the world, healthcare, and customers, while utilizing the latest technology and innovation. Head office moved to the TOKYO TORCH Tokiwabashi Tower in January 2023. Remedy group currently has offices in 8 countries. (As of September 21st, 2023)
For more information, please visit our website：https://www.remedy-company.com/